Breaking News

Syntagon Appoints New CEO

Makes changes to management team

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dr. Andis Slaitas will replace Dr. Michael Lofthagen as Syntagon’s chief executive officer. Dr. Slaitas has been with the company since 2005 and has been instrumental in developing the Syntagon Baltic chemistry facility, based in Latvia. Previously he was vice president of operations at Syntagon with responsibility for production, management and operations at the Latvian and Swedish operations.
 
The ownership of Syntagon will remain with its founders, Michael Lofthagen and Paul Alhadeff, and they will assume positions on the board of directors. Additionally, Ulrika Burén has been promoted from QA associate to QA officer. Ms. Burén joined Syntagon in 2002 as senior analytical chemist before moving to the QA department.
 
“I’m delighted to announce the appointment of Andis as chief executive officer. He has had a huge impact on Syntagon since joining the company in 2005. His competence, experience and energy will serve Syntagon well in the years ahead. Paul and I wish him all the very best,” said Dr. Lofthagen.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters